Franzè, M.S.; Filomia, R.; Caccamo, G.; Pitrone, C.; Alibrandi, A.; Saitta, C.; Caspanello, A.R.; Asero, C.; Arcadi, V.; Raimondo, G.;
et al. Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. J. Pers. Med. 2022, 12, 1794.
https://doi.org/10.3390/jpm12111794
AMA Style
Franzè MS, Filomia R, Caccamo G, Pitrone C, Alibrandi A, Saitta C, Caspanello AR, Asero C, Arcadi V, Raimondo G,
et al. Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. Journal of Personalized Medicine. 2022; 12(11):1794.
https://doi.org/10.3390/jpm12111794
Chicago/Turabian Style
Franzè, Maria Stella, Roberto Filomia, Gaia Caccamo, Concetta Pitrone, Angela Alibrandi, Carlo Saitta, Amalia Rita Caspanello, Clelia Asero, Vittoria Arcadi, Giovanni Raimondo,
and et al. 2022. "Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance" Journal of Personalized Medicine 12, no. 11: 1794.
https://doi.org/10.3390/jpm12111794
APA Style
Franzè, M. S., Filomia, R., Caccamo, G., Pitrone, C., Alibrandi, A., Saitta, C., Caspanello, A. R., Asero, C., Arcadi, V., Raimondo, G., & Cacciola, I.
(2022). Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. Journal of Personalized Medicine, 12(11), 1794.
https://doi.org/10.3390/jpm12111794
